Phase 2 study of CD-NP for treatment of acute heart failure - MPR

Links shared publicly online about this topic.

1,847
total visits

Phase 2 study of CD-NP for treatment of acute heart failure - MPR

Nile Therapeutics announced dosing of its first patient in a Phase 2 clinical study of its lead product, CD-NP, for the treatment of acute heart failure.

View full resource at empr.com

Tags: Heart, Heart Disease, Heart Failure, Phase 2 Clinical Trial, News

Most Recently Shared on August 4, 2009 at 6:11 pm By:

MPR

MPR News: Phase 2 study of CD-NP for treatment of acute heart failure: Nile Therapeutics announced dosi.. http://bit.ly/17vLAC

3 years ago...

Retweet

Favorite

Nile Therapeutics Phase 2 Study Of CD-NP In Patients With Acute Decompensated Heart Failure Meets Primary Endpoint, Has Good Trends On Renal Function

medicalnewstoday.com — “Nile Therapeutics, Inc. (Nasdaq: NLTX), a biopharmaceutical company focused on the development of novel therapeutics for cardiovascular disease, announced results of its Phase 2 study evaluating i” View full resource at medicalnewstoday.com

Most Recently Shared on November 3, 2010 at 4:06 pm By:

MNT Urology Health News

Nile Therapeutics Phase 2 Study Of CD-NP In Patients With Acute Decompensated Heart Failure Meets Primary Endpoint, Ha... http://mnt.to/3M2B

1 year ago...

Retweet

Favorite

Nile Therapeutics Phase 2 Study of CD-NP in Patients With Acute Decompensated Heart Failure Meets Primary Endpoint, Has Favorable Trends on Renal Function - MarketWatch

marketwatch.com — “Nile Therapeutics Phase 2 Study of CD-NP in Patients With Acute Decompensated Heart Failure Meets Primary Endpoint, Has Favorable Trends on Renal Function - MarketWatch” View full resource at marketwatch.com